Bifunctional small molecules targeting PD-L1/CXCL12 as dual immunotherapy for cancer treatment-Reference-Cited by-同舟云学术

Bifunctional small molecules targeting PD-L1/CXCL12 as dual immunotherapy for cancer treatment

Published:2023-03-01 Issue:1 Volume:8 Page:
ISSN:2059-3635
Container-title:Signal Transduction and Targeted Therapy
language:en
Short-container-title:Sig Transduct Target Ther

Author:

Cheng Binbin,Wang Wei,Liu Ting,Cao Hao,Pan Wei,Xiao Yao,Liu Shuwen^ORCID,Chen Jianjun^ORCID

Funder

the National Natural Science Foundation of China

the talent introduction program from Hubei Polytechnic University (No. 22xjz15R); and the Hubei Key Laboratory of Kidney Disease Pathogenesis and Intervention

the Foshan Medical Science and Technology Project grants, the Foshan Outstanding Young Medical Talents Project grants

the Wuhan Municipal Health Commission of China

the Scientific and Technological Key Projects of Guangdong Province

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics

Link

https://www.nature.com/articles/s41392-022-01292-5.pdf

Reference5 articles.

1. Wang, T. et al. Discovery of small-molecule inhibitors of the PD-1/PD-L1 axis that promote PD-L1 internalization and degradation. J. Med. Chem. 65, 3879–3893 (2022).

2. Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl Acad. Sci. USA 110, 20212–20217 (2013).

3. Tang, T. et al. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct. Target Ther. 6, 72 (2021).

4. Cheng, B., Ren, Y., Cao, H. & Chen, J. Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1. Eur. J. Med. Chem. 199, 112377 (2020).

5. Hachet-Haas, M. et al. Small neutralizing molecules to inhibit actions of the chemokine CXCL12. J. Biol. Chem. 283, 23189–23199 (2008).

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CXCR7 activation evokes the anti-PD-L1 antibody against glioblastoma by remodeling CXCL12-mediated immunity;Cell Death & Disease;2024-06-19

2. Discovery of Small and Bifunctional Molecules Targeting PD-L1/CD73 for Cancer Dual Immunotherapy;Journal of Medicinal Chemistry;2024-05-15

3. Discovery of Novel Small-Molecule-Based Potential PD-L1/EGFR Dual Inhibitors with High Druggability for Glioblastoma Immunotherapy;Journal of Medicinal Chemistry;2024-05-13

4. Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges;Frontiers in Immunology;2024-04-10

5. Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway;Journal of Medicinal Chemistry;2024-04-10